USPTO Proposes Rule and Director Implements Policy Likely to Limit Multiple Patent Validity Challenges
On Friday, October 17, the USPTO published a proposed rule that, if implemented, would likely reduce filings of inter partes review patent validity challenges. In addition, USPTO Director John Squires...
Expert Testimony Fails to Support Jury’s Infringement Verdict
FINESSE WIRELESS LLC v. AT&T MOBILITY LLC Before Moore, Linn, and Cunningham. Appeal from the United States District Court for the Eastern District of Texas. Summary: Unclear and internally inconsistent...
Similar Does Not Mean Identical
APEX BANK v. CC SERVE CORP. Before: Hughes, Moore, and Cunningham. Appeal from the Trademark Trial and Appeal Board (the “Board”). Summary: The Board erred by excluding evidence of marks...
Cooperation With a Restriction Requirement May Result in Disavowal of Claim Scope
FOCUS PRODUCTS GROUP INTERNATIONAL, LLC v. KARTRI SALES CO., INC. Before Moore, Clevenger, and Chen. Appeal from United States District Court for the Southern District of New York Summary: Repeatedly acquiescing...
$10 million to $1: Exclusion of Damages Expert Results in Nominal Damages for Surgical Stapler Patent Infringement
REX MEDICAL, L.P. v. INTUITIVE SURGICAL, INC. Before Dyk, Prost, and Stoll. Appeal from the United States District Court for the District of Delaware. Summary: Damages testimony was excluded for failing...
Standing or Guesswork? A Speculative Risk of Patent Cancellation is Insufficient for Standing
US INVENTOR, INC. v. UNITED STATES PATENT AND TRADEMARK OFFICE Before Lourie, Reyna, and Stark. Appeal from the United States District Court for the District of Columbia. Summary: Appellants who...
FCC Launches “Space Month” to Boost U.S. Space Economy
On October 6, 2025, FCC Chairman Brendan Carr declared October 2025 “Space Month” in an effort “to boost our country’s space economy.” The FCC’s stated goal for Space Month “is...
New FDA Program Prioritizes Review of Certain ANDAs
On October 3, 2025, the U.S. Food and Drug Administration (FDA) unveiled a pilot prioritization program that provides for accelerated review of abbreviated new drug applications (ANDAs) for generic companies...
What Do Businesses Need to Know About Federal and State AI Disclosure Regulation?
State Spotlight: Utah Key Takeaways With companies increasingly integrating artificial intelligence into their workflows, it is important to monitor and adapt to a patchwork of AI disclosure laws across jurisdictions....
